# Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

> **NCT00482378** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 39 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm
- Pain

## Interventions

- **DRUG:** Pamidronate
- **DRUG:** Zoledronic acid
- **RADIATION:** Sm 153 lexidronam

## Key facts

- **NCT ID:** NCT00482378
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03-21
- **Primary completion:** 2007-05-22
- **Final completion:** 2008-12-02
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2018-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482378, "Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00482378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*